Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.23.16_SUPPL.5533
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Clinical Predictors of Laryngeal Preservation Rate in Stage III-IV Laryngeal Cancer and Hypopharyngeal Cancer Patients Treated with Organ Preservation

  2019cites this paper
• Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.

  2017cites this paper
• ORGANOPRESERVACIÓN NO QUIRÚRGICA EN CÁNCER DE CABEZA Y CUELLO Nuevas perspectivas de manejo conservador en los pacientes con tumores avanzados de cabeza y cuello

  2016cites this paper
• A genetic view of laryngeal cancer heterogeneity

  2016cites this paper
• MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer

  2015cites this paper
• SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013

  2013cites this paper
• Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891.

  2012cites this paper
• EGFR, HER2 and VEGF Pathways

  2012cites this paper
• Larynx preservation: what is the standard treatment?

  2012cites this paper
• Terapia medica integrata nei carcinomi squamocellulari

  2011cites this paper
• Carcinoma dell’ipofaringe

  2011cites this paper
• SEOM clinical guidelines for the treatment of head and neck cancer

  2010cites this paper
• Prognostic and predictive significance of p53, EGFr, Ki-67 in larynx preservation treatment.

  2010cites this paper
• Radiotherapy and Chemotherapy of Squamous Cell Carcinomas of the Hypopharynx and Esophagus

  2010cites this paper
• Candidates for larynx preservation: the next step?

  2010cites this paper
• Integrating biologically targeted therapy in head and neck squamous cell carcinomas.

  2009cites this paper
• Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial

  2009cites this paper
• Surgery for Laryngopharyngeal SCC in the Era of Organ Preservation

  2009cites this paper
• Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.

  2009cites this paper
• Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know?

  2008cites this paper
• Antibody Therapy of Cancer

  2008cites this paper
• The molecular genetics of laryngeal cancer.

  2008cites this paper
• Cetuximab, its clinical use and future perspectives.

  2008cites this paper
• Immunotherapy for head and neck cancer.

  2008cites this paper
• Swing of the pendulum: Optimizing functional outcomes in larynx cancer

  2008cites this paper
• [Organ preservation in laryngeal and hypopharyngeal cancer].

  2007cites this paper
• Combination of radiotherapy with EGFR antagonists for head and neck carcinoma

  2007cites this paper
• Tumores del área ORL. Tratamiento de quimiorradioterapia

  2007cites this paper
• EGFR-targeted Therapy in Head and Neck Squamous Cell Carcinoma

  2007cites this paper
• Modalidades de preservación de órgano en carcinomas de laringe e hipofaringe

  2007cites this paper
• Laryngeal preservation in head and neck cancer: multidisciplinary approach.

  2006cites this paper
• Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents

  2006cites this paper
• Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

  2006cites this paper
• Clinical implications of the mechanism of epidermal growth factor receptor inhibitors

  2006cites this paper
• Radiation combined with EGFR signal inhibitors: head and neck cancer focus.

  2006cites this paper
• Epidermal growth factor receptor directed therapy in head and neck cancer.

  2006cites this paper